Navigation Links
Probability of Lung Cancer Overdiagnosis with LDCT Screening Addressed Using NLST Data
Date:12/9/2013

Philadelphia, PA (PRWEB) December 09, 2013

An analysis of data from the National Lung Screening Trial (NLST), the results of which were published today in JAMA Internal Medicine, suggests that more than 18 percent of lung cancers detected by low-dose computed tomography (LDCT or low-dose CT) may be indolent.

“This is another important piece of information that helps us to better understand the benefits and risks of lung cancer screening,” said the study’s lead author Edward F. Patz, Jr., MD, James and Alice Chen Professor of Radiology and Professor of Pathology, Pharmacology, and Cancer Biology, Duke University School of Medicine, Durham, NC. “The NLST provided encouraging data demonstrating that lung cancer screening with low-dose CT reduces death from the disease. Despite this good news, however, there are inherent risks in any mass screening program, and one of those risks is the probability of overdiagnosis.”

Overdiagnosis seeks to detect occult disease in asymptomatic individuals and is often an intrinsic feature of screening, Patz went on to explain. In the current study, overdiagnosis was defined as the detection of a cancer that would not otherwise have become clinically apparent.

Study investigators found that the probability that any lung cancer (all types and stages) detected by LDCT screening represented an overdiagnosis was 18.5 percent. The probability that an LDCT-detected non-small cell lung cancer—by far the most frequently diagnosed lung cancer type—represented an overdiagnosis was 22.5 percent. The overdiagnosis rate for bronchoalveolar lung cancer with LDCT screening was 78.9 percent.

“In current clinical practice, patients with nonaggressive lung cancers are treated the same as any other patient with lung cancer, because it is generally not possible to distinguish indolent lesions from more aggressive tumors,” Patz said. “Better biomarkers and imaging techniques are needed to determine the aggressiveness of the lung cancer, so as to optimize patient care and enhance the value of screening programs.”

Patz further explained that the possibility of overdiagnosis in lung cancer is not as widely considered as that in other cancers, such as prostate cancer. “When patients are diagnosed with lung cancer, it’s most often viewed as a fatal disease; however, data from our analysis confirm that that’s not necessarily the case in screening programs, which is important information for clinicians to discuss with their patients,” he said.

The authors described several negative consequences of overdiagnosis, including unnecessary invasive diagnostic procedures, treatment, morbidity (and mortality in rare cases), follow-up, cost, patient anxiety, and the labeling of patients with a disease that would otherwise never have been detected.

“The relatively modest rate of overdiagnosis with low-dose CT, compared with the overdiagnosis rate projected for other cancer screening programs, further supports the implementation of lung cancer screening initiatives,” said Mitchell D. Schnall, MD, PhD, Group Co-Chair, ECOG-ACRIN Cancer Research Group; Eugene P. Pendergrass Professor of Radiology; and Chair, Radiology Department, University of Pennsylvania Perelman School of Medicine, all in Philadelphia, PA. “Of course, it’s important that we work to further drive down overdiagnosis rates across all screening programs.”

About the National Lung Screening Trial

The National Lung Screening Trial, which was conducted by the American College of Radiology Imaging Network (ACRIN) and the Lung Screening Study Group of the National Cancer Institute, part of the National Institutes of Health, randomly assigned 53,454 individuals at high risk of lung cancer to receive either three annual low-dose computed tomography (LDCT) scans or chest x-rays (CXRs) at 1 of 33 medical centers in the United States. Study participants were followed for up to 5 years. The primary trial objective was to determine the effect of screening with LDCT vs. CXR on lung cancer mortality. Results of NLST, which were published in the New England Journal of Medicine (2011), demonstrated a 20 percent relative reduction in lung cancer-specific mortality with LDCT.

About the ECOG-ACRIN Cancer Research Group

The ECOG-ACRIN Cancer Research Group is a multidisciplinary, membership-based scientific organization that designs and conducts biomarker-driven cancer research involving adults who have or are at risk of developing cancer. The Group was formed in May 2012 by a merger that combined the complementary strengths of the Eastern Cooperative Oncology Group (ECOG) in cancer therapy and the American College of Radiology Imaging Network (ACRIN) in cancer imaging. ECOG and ACRIN were two highly respected National Cancer Institute (NCI)-sponsored cancer cooperative groups. ECOG-ACRIN comprises nearly 650 member institutions in the United States and around the world. Approximately 6000 physicians, translational scientists, and associated research professionals from the member institutions are involved in Group research, which is organized into three scientific programs: Cancer Control and Outcomes, Therapeutic Studies, and Biomarker Sciences. ECOG-ACRIN is supported primarily through NCI research grant funding, but also receives funding from private sector organizations through philanthropy and collaborations. It is headquartered in Philadelphia, PA, as is PrECOG, LLC, a not-for-profit company that partners with ECOG-ACRIN and industry to develop and conduct clinical trials in all areas of oncology. For more information, visit http://www.ecog-acrin.org or call 215.789.3631.
###

Read the full story at http://www.prweb.com/releases/2013/12/prweb11404463.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. New Stool Test Might Aid in Early Detection of Colon Cancer
3. Study reveals how cancer drug causes diabetic-like state
4. How a cancer drug leads to diabetes
5. You Survived Cancer: Now Pay Attention to Your Overall Health
6. New drug prevents spread of human prostate cancer cells
7. Eliminating the good cholesterol receptor may fight breast cancer
8. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
9. Experimental Chemo Combo for Colon Cancer Disappoints
10. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
11. Targeted therapeutics for colon cancer to be presented at AACR meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... DIEGO, California (PRWEB) , ... June 20, 2017 ... ... product documentation and help content solutions for the enterprise, is proud to announce ... properties, including CRM, e-commerce, ticketing systems, company websites, and more to provide a ...
(Date:6/20/2017)... Cincinnati, Ohio (PRWEB) , ... June 20, 2017 ... ... with gum disease in Cincinnati, OH for leading-edge care, whether or ... advances in laser dentistry. Using the BIOLASE WaterLase® iPlus™ laser, she targets bacteria ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience ... in Denville, NJ, Drs. Adam and Hal Kimowitz are currently accepting new patients at ... traditional orthodontics can cause for some patients, which is why they offer the latest ...
(Date:6/20/2017)... ... June 20, 2017 , ... This year, participants ... focused on finding product improvements that could reduce the occurrence of unplanned extubations ... need help breathing or to provide medication. Sometimes, patient movement can cause unplanned ...
(Date:6/20/2017)... , ... June 20, 2017 , ... ... makers of SweetLeaf® Stevia Sweetener, Michael P. May, Ph.D., recently accepted the distinguished ... Export Recognition Program selected Wisdom Natural Brands (WNB), and 16 other businesses from ...
Breaking Medicine News(10 mins):
(Date:6/12/2017)... June 12, 2017 Kineta, Inc., a biotechnology company ... Kineta Vice President of R&D and Head of Virology ... Pandemic Preparedness for the Northwest and Beyond meeting sponsored ... June 14, 2017 from 8:30-10:30 AM PDT at the Agora ... Dr. Bedard will be joined by other leaders ...
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 6, 2017  Diplomat Specialty Infusion Group, a brand of ... to its Iowa location. The ... now features an ISO 7 cleanroom—the standard needed to compound ... a low level of pollutants. ... consumers and better serve our Iowa patients," ...
Breaking Medicine Technology: